iShares Genomics Immunology and ETF News

Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the iShares Gen

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

The overall price growth since the inception of IDNA is quite impressive, considering the huge impact of the Covid-19 pandemic in the U.S. equity market. Huge price loss in the past 12 months, but pos

Currently, 66 ETFs are affected, but it will be added to even more funds soon.

What to consider for thematic ETFs in 2022 and beyond.

Investment strategies geared to the future evaluate complex dynamics that can evolve rapidly. As innovation's market share has grown, investment capacity - as measured by average days to trade - also

Pharma/biotechnology is the most attractive healthcare subsector. Life science tools have performed the best in one year, but are overvalued now.

Related Stocks: VB , FSMB , SCHD , ICLN , MSA , IDNA , GE , SPYD , WMB , RDVY , ALLY , ROKU , ALXN , PACW , QCLN , USMV , BUD ,

Join us for a triple-header to determine the best genomics biotech ETF!

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month.

IDNA: Genetics Now Have A Lot Of Influence On Healthcare

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.